MBD4 and neoplasm: If only the difference in tumor burdens between the two genotypes within each experiment is considered, this result would appear to support the conclusion that replacement of Mbd4−/− hematopoietic cells with WT reduces the tumor burden in AOM/DSS treated Mbd4−/− mice to WT levels.